Figure 12. Axitinib blocks binding of VEGF to its receptor, VEGFR2 and prompts a loss of Bcl-2 levels. Cell lysates collected from cells treated with 0.05 µM, 0.5 µM, and 5 µM of axitinib (AG013736) were analyzed with western blot analysis for the BAX and Bcl-2 levels. There was no change in the protein levels of BAX, and a significant decrease in the levels of Bcl-2 was observed with the VEGF receptor inhibitor (A). B and C represent the corresponding densitometry analysis.